Access to Clinical Trials
Thursday, 19 November 2026
Contributions
Question
Asked by
Baroness Pidgeon
To ask His Majesty’s Government what steps they are taking to speed up access to clinical trials.
The Parliamentary Under-Secretary of State, Department of Health and Social Care (Baroness Merron) (Lab)
My Lords, we have fast-tracked clinical trials to give patients quicker access to more innovative treatments. In the first three months of this year, all eligible commercial clinical trials were set up in less than 150 days, meeting our Life Sciences Sector Plan target. We have achieved this by cutting bureaucracy and increasing NHS accountability, and we are investing in research infrastructure to support participation in all types of clinical trials across the country.
Baroness Pidgeon (LD)
The Government have made welcome progress in speeding up commercial clinical trials, but over 95% of patients take part in non-commercial interventional trials, often funded by charities. Cancer Research UK expects 80,000 people to participate in its trials over the next five years, so what steps will the Government take to speed up these types of trials to help find treatments for rarer conditions?
Baroness Merron (Lab)
I am glad that the noble Baroness recognises the progress, because this is a success story in the making. We have more to do, of course. On non-commercial trials, we want all eligible studies to be set up within 150 days or fewer; therefore, the things that we apply in the commercial setting also apply. I should say to the noble Baroness that the data suggests that actions to accelerate commercial trials have also improved set-up times, but we will be publishing an update on this early next year.
Baroness Finlay of Llandaff (CB)
My Lords, can the Minister tell us what powers the rare cancers lead will have to ensure that all patients with rare cancers have rapid direct contacts to clinical trials relevant to their diagnosis, and to allow participation across the whole of the UK and therefore be able to work with devolved Governments as well?
Baroness Merron (Lab)
We work closely with the devolved Administrations so that we can extend this UK-wide. As the noble Baroness will know, the national cancer plan includes a dedicated chapter for action on rare and less common cancers, including how we will make them a research priority and implement this year’s Rare Cancers Act to give more patients access to clinical trials in respect of rare cancers. There are two complementary roles: we have Dr Metcalf driving clinical improvement and delivery through the national cancer board, as the national cancer lead, but we also have Dr Stoneham, who has been appointed as the NIHR national specialty lead for rare cancers, and that will provide dedicated leadership.
Baroness Ritchie of Downpatrick (Lab)
My Lords, with the 10-year workforce plan expected, can my noble friend the Minister indicate whether the Government will commit to protected research time in staff job plans and new investment in the workforce that clinical trials depend on? I declare that I am somebody who benefited from a clinical trial.
Baroness Merron (Lab)
I am glad to hear that my noble friend benefited in that way. She makes an important point about the centrality of research in delivering our 10-year health plan, particularly that staff need the capacity to undertake it. I know that my noble friend would not expect me to pre-empt the 10-year workforce plan, but I can say that we are working with research funders so as to strengthen clinical academic career pathways through providing additional training places. We are also strengthening post-doctoral support and clearer funding opportunities, because we need the workforce capacity that she refers to.
Baroness Blackwood of North Oxford (Con)
My Lords, I declare an interest as chair of the Health Data Research Service. The UK has globally competitive health data, but at the moment it is still painfully slow to access. Improving that access and the methods by which we do it is crucial to improving clinical trials. We have made a great deal of progress in setting up HDRS in the first instance, but we will be successful only with partnership across the health system and full-throated support from the Government. Can the Minister confirm that we have their support and how they intend to implement it going forward?
Baroness Merron (Lab)
Yes, indeed. I agree with the noble Baroness and am grateful for her recognition of the advances that are being made and will continue to be made. The use of data is absolutely key, and I will be pleased to write to her with further detail on exactly how we are doing that.
Lord Mohammed of Tinsley (LD)
Perhaps I might build upon the question just asked by the noble Baroness to ask about ensuring that the data collected includes people from diverse backgrounds, particularly those from disadvantaged backgrounds, who often suffer from ill-health more than others. How will the Government ensure that the data and the trials taking place include people from diverse and poorer backgrounds?
Baroness Merron (Lab)
All the work that we are doing, including the establishment of the NIHR research infrastructure, the main vehicle for delivering clinical trials, is through the research delivery network. At its core, that is about ensuring the breadth of inclusion for people who should be part of clinical trials, but I also emphasise our work in ensuring that people come forward. We are making it easy to come forward and take part; that includes being able to register through the NHS app—something that was not available beforehand.
Lord Patel (CB)
My Lords, to follow up on the question from the noble Baroness, Lady Blackwood, does the Minister agree that access to the single patient record, once it is established, will speed up the process of recruiting patients for clinical trials? That is the major cause of the delay in setting up clinical trials. It is therefore important that single patient records are not solely set up for the management of a patient’s care; the full record should be available for patients with similar diseases.
Baroness Merron (Lab)
The single patient record, which we are discussing as part of the Health Bill that is being debated in this Chamber, is absolutely crucial. The main focus, as the noble Lord says, is of course on the ability for information about a patient to travel with them. That will indeed remain the focus. I think we need to look at the potential for future uses, but I take on board the point that he makes.
Lord Kamall (Con)
My Lords, building on the question from the noble Lord, Lord Mohammed, regarding concerns about access to trials for people from ethnic backgrounds, there are also concerns that access to clinical trials often depends on where a patient happens to live or what hospital they attend. Given this, what is the Minister’s department doing to ensure that patients who live away from major teaching hospitals, particularly those in rural and underserved areas, have a genuine and feasible opportunity to participate in clinical trials?
Baroness Merron (Lab)
I referred earlier to the research delivery network. I have been looking at where the commercial research delivery centres are: there are 35 of them and they have been established to support the delivery of commercial trials across the UK. That includes 14, for example, in primary care sites. The point the noble Lord makes is absolutely right. As I said, that is why it is hard-wired throughout all the changes that we have made to make the improvements that we have.
Lord McColl of Dulwich (Con)
My Lords, will the Minister kindly consider the idea that we ought to inform the public that patients who are included in clinical trials often do better than those who are not so included?
Baroness Merron (Lab)
When I have met people who have come forward and, indeed, been encouraged to take part in clinical trials, there are several reasons that they have come forward: one of them is the point made by the noble Lord about access to possibilities that they could not otherwise access; for others, their motivation is that they just want to help others in the future. Both motivations are legitimate, and we ensure that they are discussed with individuals.
Source: UK Parliament Hansard API. Debate ID: 5441469.